Mounjaro indications: the conditions tirzepatide is licensed to treat

Step 1, understanding the two licensed indications for Mounjaro in the UK

Tirzepatide received MHRA approval in the UK under the brand name Mounjaro for two separate clinical purposes. The first is weight management: adults with a BMI of 30 kg/m² or above, or a BMI of 27–29.9 with at least one weight-related comorbidity, may be considered. Qualifying conditions in that second group include type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea and cardiovascular disease, among others. For some ethnic backgrounds (including South Asian, Chinese, Middle Eastern, Black African or African-Caribbean) the BMI thresholds sit 2.5 kg/m² lower under current UK clinical guidance.

The second indication is glycaemic control in adults with type 2 diabetes, where tirzepatide is used alongside diet and exercise, and sometimes alongside other antidiabetic medicines, a topic explored in detail on our page covering Mounjaro and other medications. This is a distinct licence: a prescriber who recommends Mounjaro for weight management in someone who also has diabetes is working within the weight management indication, not the diabetes one, depending on the clinical picture. That distinction matters for how treatment is framed and reviewed.

Both indications carry a Black Triangle (▼) designation, meaning the MHRA requires additional monitoring of tirzepatide while post-market data accumulates. You can read the full patient-facing information on the NHS tirzepatide medicines page, which covers both licensed uses.

Step 2 (what the indication means for how treatment is structured

A licence indication is not just a label) it shapes the entire treatment plan. For the weight management indication, the prescriber is looking at BMI, the presence of weight-related conditions, your medical history, current medicines and contraindications. Treatment is intended to be used alongside a reduced-calorie diet and increased physical activity; Mounjaro is an adjunct, not a replacement for those changes.

The dose sequence starts at 2.5 mg, which exists to let your body adjust rather than to produce meaningful weight loss at that level. Titration follows in steps set by the prescriber, typically at four-week intervals, up to a maximum of 15 mg. At every dose review, the clinical picture is reassessed. On the Mounjaro medication overview you'll find more on how the titration schedule is managed in practice.

For the diabetes indication the calculus is somewhat different: the prescriber is balancing HbA1c targets, other antidiabetic treatments, kidney function and cardiovascular risk. People using Mounjaro for diabetes who are also living with obesity may see significant weight reduction (that is an expected, documented effect, not an off-label benefit) but the indication governing that prescription remains diabetes management.

Step 3, what NICE recommends, and how NHS access relates to the licensed indication

Holding a licence and being recommended by NICE for NHS use are two separate things. NICE's technology appraisal TA1026, published in December 2024, recommends tirzepatide for weight management on the NHS for adults with a BMI of 35 or above plus at least one weight-related comorbidity, used within a specialist weight management service. That recommendation comes with a phased rollout (NHS access is being expanded in stages through 2025 to 2027) and is narrower than the full licensed population. A detailed breakdown of the current NHS eligibility phases is on our Mounjaro overview page.

Private prescribing, by contrast, can extend to the full licensed population: adults with BMI ≥30, or ≥27 with a qualifying condition, subject to a prescriber's individual clinical assessment. That assessment might conclude that Mounjaro is not suitable even if you meet the BMI threshold, and our page on Mounjaro contraindications explains the medical and clinical factors that can rule out a prescription at that stage. The NICE TA1026 guidance sets out the NHS recommendation in detail, including the evidence base the committee reviewed.

One thing worth knowing about the interaction between licensed indications and other medicines: some drugs affect how tirzepatide works, or vice versa, and that is part of what a prescriber reviews before approving any prescription. You can find a thorough breakdown of this topic on our page covering Mounjaro medication interactions, which goes into specific drug combinations and how they are assessed.

Step 4, what sits outside the licensed indications

The MHRA and DHSC have stated clearly that GLP-1 medicines are not assessed for quick or cosmetic weight loss, and that these are not appropriate uses of the medicine. Mounjaro is licensed for clinically meaningful weight management in people who meet specific criteria, not for people within a healthy BMI range who want to lose a small amount of weight for aesthetic reasons. Any UK prescriber working within the law will decline to prescribe outside the licensed indications.

It is also worth being clear about what Mounjaro is not. It is not the same as Ozempic (semaglutide), which is licensed for type 2 diabetes in the UK, not weight loss. And it is not Zepbound, which is the US brand name for tirzepatide and has no UK authorisation. Understanding which medicines hold which UK indications matters more than you might expect when you're navigating a crowded market. Our page on GLP-1 medications including tirzepatide sets out those distinctions. If you have any remaining questions about whether the tirzepatide indications apply to your situation, speaking to our prescribers is the right next step, they review every consultation personally, and there is no obligation to proceed.